APA (7th ed.) Citation

H, Y., J, M., E, F., WI, B., JM, B., M, N., . . . RM, R. (2019). Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. British journal of haematology, 185(3), 492. https://doi.org/10.1111/bjh.15806

Chicago Style (17th ed.) Citation

H, Yimer, et al. "Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study." British Journal of Haematology 185, no. 3 (2019): 492. https://doi.org/10.1111/bjh.15806.

MLA (9th ed.) Citation

H, Yimer, et al. "Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study." British Journal of Haematology, vol. 185, no. 3, 2019, p. 492, https://doi.org/10.1111/bjh.15806.